1. Introduction {#sec1}
===============

*Achromobacter xylosoxidans* subspecies*denitrificans* is a gram-negative bacillus recently emerging as a causative agent of infection \[[@B1]\]. The*Achromobacter*species has many subspecies the most clinically important of which are*xylosoxidans* and*denitrificans* \[[@B1]\]. There are infrequent reports of infections with this organism involving various organs ([Table 1](#tab1){ref-type="table"}). It seems that a dysfunctional immune status and/or prior structural damage plays a role in the pathogenicity*Achromobacter xylosoxidans,*subspecies*denitrificans*. We report a rare case of pneumonia due to this organism in a 45-year-old female with bronchiectasis secondary to recurrent aspiration.

2. Case Presentation {#sec2}
====================

This is a 45-year-old White female with past medical history of asthma and gastroesophageal reflux disease (GERD) treated with Nissen fundoplication in the past. She presented to our clinic with chronic cough productive of greenish sputum. She improved with previous antibiotic use of levofloxacin on several occasions but her symptoms would recur as soon as she stops the antibiotics. Chest X-ray at initial evaluation showed an infiltrate bilaterally more pronounced on the right lower lobe. A CT scan of the chest was obtained and confirmed the infiltrates and showed bronchiectatic changes bilaterally in the lower lobes ([Figure 1](#fig1){ref-type="fig"}). Her autoimmune screen came back negative for rheumatoid arthritis and Sjogren\'s syndromes, yet her immunoglobulins were elevated and her alpha one antitrypsin and immunoglobulin E (IgE) were at normal levels. Her sweat chloride test was normal. Chronic recurrent aspiration was suspected and an esophageal PH monitor along with esophageal manometry confirmed our suspicion of chronic aspiration secondary to severe acid reflux with elevated DeMeester score. Bronchoscopy was performed to rule out an obstructive disease and to obtain samples to rule out mycobacterial disease. Cultures came back positive for heavy growth of a nonfermenter later identified as*Achromobacter xylosoxidans,*subspecies*denitrificans*. Sensitivities were evaluated and the bacteria was sensitive to levofloxacin, amikacin, cefepime, ceftazidime, gentamicin, meropenem, piperacillin/tazobactam, tobramycin, and trimethoprim-sulfamethoxazole. It was found to be resistant to aztreonam, cefotaxime, and ciprofloxacin, with incubation period of 5 days. Airway clearance techniques with percussion and flutter valve and bronchodilator therapy with hypertonic saline nebulizers were initiated. She was started on a 3-week course of levofloxacin but her symptoms recurred one month after stopping the antibiotic despite airway clearance techniques. She was started again on levofloxacin for two more weeks with good clinical response and no recurrence of symptoms after a total 5 weeks of antibiotic therapy. She was referred for surgical intervention to abolish the ongoing injury to the airway and stop the aspiration insult to the airways.

3. Discussion {#sec3}
=============

*Achromobacter denitrificans* is an aerobic, nonglucose fermenter gram-negative bacillus and flagellated and motile and produces acid from xylose \[[@B1]\]. The genus*Achromobacter*has multiple subspecies:*xylosoxidans, ruhlandii, piechaudii*,*denitrificans, spanius, insolitus,* and*marplatensis*. The most clinically significant subspecies are*Achromobacter xylosoxidans* and*denitrificans*\[[@B2]\]. It can be found in nature in soil, and the*xylosoxidans* subspecies has an affinity for aquatic surfaces. There are more clinically significant isolates of the subspecies*xylosoxidans* compared to*denitrificans* in terms of incidence of infection and clinical variety. Reports about infections with*Achromobacter denitrificans* are rare as an emerging pathogen.

There is a multitude of respiratory system infection cases due to*Achromobacter xylosoxidans*, subspecies*xylosoxidans* but not*denitrificans* \[[@B3]\]. The first reported pneumonia case due to*Achromobacter denitrificans* was reported from India in a 48-year-old male clerk in a chemical factory. It was isolated from sputum at two different occasions with no other concomitant isolates. It was sensitive to meropenem, imipenem, piperacillin-tazobactam, ticarcillin, trimethoprim-sulfamethoxazole, and third-generation cephalosporins. It was successfully treated with two weeks of meropenem \[[@B4]\]. Our case is to date the second reported case of*Achromobacter xylosoxidans* subspecies*denitrificans*. Other reported infections in adults include meningitis \[[@B5]\], endocarditis \[[@B6]\], endocarditis with aortic root abscess \[[@B7]\], renal abscess \[[@B8]\], peritoneal dialysis catheter related peritonitis \[[@B9]\], and exit site infection \[[@B10]\] ([Table 1](#tab1){ref-type="table"}).

Diagnosis depends on isolation of the organism depending on site of the infection. So far, we have reported isolates from septum, pus, peritoneal fluid, and cerebrospinal fluid ([Table 1](#tab1){ref-type="table"}). Identification can be via standard culturing methods. In our case bronchoalveolar lavage samples have been incubated in Blood Agar (TSA with 5% Sheep Blood)/MacConkey Agar Plate using a BioMérieux VITEK-2 system, incubated at 36-37 degrees Celsius.

The immunosuppressed population are at higher risk of infection due to*Achromobacter* species \[[@B3]\], yet as seen in [Table 1](#tab1){ref-type="table"} most of the patients had not been overtly immunocompromised but may have had predisposing conditions (end stage renal disease, presence of catheters, etc.). Both cases with involvement of respiratory system had a background of bronchiectasis. The former \[[@B4]\] was most likely secondary to tuberculosis while in our case it is most likely secondary to recurrent aspiration. We theorize that the damaged bronchiectatic lung tissue predisposed to the infection with this organism. This had been illustrated before in that*Achromobacter*species is known to colonize and infect cystic fibrosis patients \[[@B12]\]. In the other reported cases ([Table 1](#tab1){ref-type="table"}), we can notice that structural damage and/or foreign body had been present: previous trauma, prosthetic valve, peritoneal dialysis catheter, and renal stones. Pathogenicity of*Achromobacter* species has been previously studied \[[@B13]\] with demonstrated ability to form biofilms and motility (via pili and flagella) which can potentiate infections in setting of structural damage and devices.

Management depends on administration of appropriate antibacterial agents, yet duration of treatment is not exactly defined due to lack in specific guidelines in this regard. The cases reported so far ([Table 1](#tab1){ref-type="table"}) had been managed with different regimens but the most palpable response was to carbapenems with durations ranging from 2 to 14 weeks ([Table 1](#tab1){ref-type="table"}). The sensitivity of the isolates is outlined below in [Table 1](#tab1){ref-type="table"}, but the*Achromobacte*r species had been historically responsive to antipseudomonal agents \[[@B1]\] with various success rates depending on site of infection and complexity of the cases. Our patient was cured after 5 weeks of oral levofloxacin therapy (after initial failure after three weeks). The outcome is generally excellent with clearance of the infection.

4. Conclusion {#sec4}
=============

Rare causes of pneumonia should be investigated since appropriate detection can facilitate accurate antibacterial management. We theorize that structural damage (bronchiectasis secondary to chronic aspiration) plays a role in the pathogenesis of pneumonia in our patient. Combined management with antibiotics and airway clearance techniques resulted in an excellent outcome.
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###### 

Previous reports of infections with *Achromobacter xylosoxidans subspecies denitrificans*, detailing type of infection, antimicrobial sensitivity, and duration of treatment.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year reported    Type of infection              Isolation specimen                      Comorbid conditions                             Sensitivity                                                                   Antibiotic of choice                      Treatment duration
  ---------------- ------------------------------ --------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------- --------------------------------------------------------------
  2011\            Prosthetic\                    Blood                                   Tetralogy of Fallot                             Cefepime, ceftazidime, ciprofloxacin, imipenem, levofloxacin\                 Piperacillin/tazobactam\                  6 weeks of piperacillin/tazobactam, then 8 weeks of imipenem
  \[[@B6]\]        valve\                                                                                                                 Piperacillin/tazobactam\                                                      (not specified), then imipenem            
                   endocarditis                                                                                                           Ticarcillin/clavulanic acid, trimethoprim-sulfamethoxazole                                                              

                                                                                                                                                                                                                                                                  

  2011\            Meningitis                     Cerebrospinal fluid                     Prostatic\                                      Not reported                                                                  Meropenem 2 g\                            15 days
  \[[@B5]\]                                                                               adenocarcinoma\                                                                                                               intravenously (IV)                        
                                                                                          Epilepsy\                                                                                                                                                               
                                                                                          Hyperlipidemia\                                                                                                                                                         
                                                                                          Atrial fibrillation\                                                                                                                                                    
                                                                                          Remote history of cranial trauma                                                                                                                                        

                                                                                                                                                                                                                                                                  

  2014 \[[@B9]\]   Peritoneal dialysis\           Pus collected from exit site            Diabetes mellitus, chronic kidney\              Not reported                                                                  Ciprofloxacin 250 mg every twelve hours   14 days
                   catheter\                                                              disease (near end stage renal disease)                                                                                                                                  
                   Exit\                                                                                                                                                                                                                                          
                   site infection                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                  

  2012\            Right renal abscess with\      Pus collected from intrarenal abscess   Hypertension, chronic kidney disease, benign\   Colistin, imipenem, meropenem,\                                               Meropenem 1 g IV                          60 days
  \[[@B8]\]        renocutaneous\                                                         prostatic hyperplasia\                          piperacillin/tazobactam                                                                                                 
                   fistula                                                                Recurrent bilateral nephrolithiasis                                                                                                                                     

                                                                                                                                                                                                                                                                  

  2013\            Prosthetic valve\              Blood                                   Congenital aortic stenosis, history of\         Not reported                                                                  Meropenem, trimethoprim-\                 4 weeks
  \[[@B7]\]        endocarditis\                                                          aortic valve valvotomy                                                                                                        sulfamethoxazole,\                        
                   with aortic root abscess                                                                                                                                                                             then levofloxacin                         

                                                                                                                                                                                                                                                                  

  2014\            Pneumonia                      Sputum                                  History of tuberculosis                         Meropenem, imipenem, piperacillin/tazobactam,\                                Meropenem 1 g q 8 hours                   2 weeks
  \[[@B4]\]                                                                                                                               ticarcillin, trimethoprim-sulfamethoxazole, third-generation Cephalosporins                                             

                                                                                                                                                                                                                                                                  

  2014\            Peritoneal dialysis\           Effluent dialysate                      End stage renal disease on peritoneal\          Ciprofloxacin (other antibiotics not specified)                               Ciprofloxacin\                            Duration not specified
  \[[@B9]\]        Catheter related peritonitis                                           dialysis                                                                                                                      (not specified)                           

                                                                                                                                                                                                                                                                  

  2017             Current case Pneumonia /\      Bronchoalveolar lavage                  Gastroesophageal reflux disease, asthma         Amikacin, cefepime, ceftazidime, gentamicin,\                                 Levofloxacin                              6 weeks
                   Bronchiectasis                                                                                                         levofloxacin, meropenem,\                                                                                               
                                                                                                                                          piperacillin/tazobactam, tobramycin,\                                                                                   
                                                                                                                                          trimethoprim/sulfamethoxazole                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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